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Abstract: Delays in diagnosing breast cancer (BC) can lead to poorer outcomes. We investigated
factors related to the diagnostic interval in a population-based cohort of 3202 women diagnosed
with BC in Queensland, Australia. Interviews ascertained method of detection and dates
of medical/procedural appointments, and clinical information was obtained from medical
records. Time intervals were calculated from self-recognition of symptoms (symptom-detected)
or mammogram (screen-detected) to diagnosis (diagnostic interval (DI)). The cohort included
1560 women with symptom-detected and 1642 with screen-detected BC. Symptom-detected women
had higher odds of DI of >60 days if they were Indigenous (OR = 3.12, 95% CI = 1.40, 6.98); lived in
outer regional (OR = 1.50, 95% CI = 1.09, 2.06) or remote locations (OR = 2.46, 95% CI = 1.39, 4.38);
or presented with a “non-lump” symptom (OR = 1.84, 95% CI = 1.43, 2.36). For screen-detected BC,
women who were Indigenous (OR = 2.36, 95% CI = 1.03, 5.80); lived in remote locations (OR = 2.35,
95% CI = 1.24, 4.44); or disadvantaged areas (OR = 1.69, 95% CI = 1.17, 2.43) and attended a public
screening facility (OR = 2.10, 95% CI = 1.40, 3.17) had higher odds of DI > 30 days. Our study
indicates a disadvantage in terms of DI for rural, disadvantaged and Indigenous women. Difficulties
in accessing primary care and diagnostic services are evident. There is a need to identify and
implement an efficient and effective model of care to minimize avoidable longer diagnostic intervals.
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1. Introduction
An estimated 1.67 million women were diagnosed with breast cancer worldwide in 2012 and rates
are continuing to rise [1]. In Australia, breast cancer is the most common cancer diagnosed amongst
women (with the exception of keratinocyte cancer) and the second leading cause of cancer death [2].
Incidence and mortality rates are similar to those observed in other developed countries [1].
Detection of breast cancer at an early stage is associated with lower mortality and improved
survival [3]. Observed five-year survival varies from 88% for stage I breast cancers to 15% for stage
IV [4]. The goal is always to diagnose cancers at the earliest possible stage providing patients with the
best possible prognosis. The majority of adult cancers are slow growing, with one study suggesting
breast cancers were diagnosed, on average, approximately seven years after the initial onset [5].
However, this is dependent on a number of factors including tumour grade, rate of growth and
morphological type and likely other unknown factors [5]. Despite this variability, there is consensus
in the literature that longer intervals between first noticing a breast cancer symptom and definitive
diagnosis are associated with larger tumour size and later stage tumours [6–10]. Further, it has been
established that intervals of greater than three to six months are associated with poorer survival [6,11].
While intervals of a few days or a few weeks may not have significant impact on survival, longer
intervals in obtaining a diagnosis can mean more stress for a patient [12], and potentially more rigorous
treatment regimens and their associated side effects and morbidities for patients whose cancer proves
to be more advanced.
Timely detection and diagnosis of breast cancer requires a good awareness of the symptoms on the
part of women and doctors, an efficient and effective population-based screening program (for women
within the target age-range) and timely access to diagnostic services. However, inequalities in each of
these components are evident. In Australia, persistent inequalities in access to breast cancer screening
and diagnostic services have been documented. For example, rates of breast screening within the
BreastScreen Australia services (Australia’s publically-funded screening program for women aged
50 to 74 years) are lowest for women living in remote and very remote areas of Australia and for
Indigenous women [13]. Further, inequalities in timely access to diagnostic services have been reported
in Australia [14], and elsewhere [15–17].
While in Australia there are published General Practitioner (GP) guidelines for the investigation of
a new breast symptom [18], these do not include a recommended time period from initial presentation
to commencing relevant diagnostic procedures. However, in the United Kingdom, recommendations
state patients should receive an appointment or be seen by a specialist within 14 days of the initial GP
consultation, and women presenting with symptoms of invasive cancer should receive a diagnosis
within five working days of the initial specialist assessment [19]. In relation to screen-detected breast
cancer, there is no international consensus on the appropriate time interval for assessment following an
abnormal mammogram. BreastScreen Australia accreditation standards state that 90% of all screened
women should receive notification of their mammogram results within 14 days and 100% within
28 days [20]. The American College of Radiology recommends women should be contacted regarding
an abnormal mammography within five days [21]. Currently, only the European community have
published guidelines that include the timeliness of follow-up diagnostic procedures recommending
this should begin within five days of notification of an abnormal mammogram [22].
Various definitions have been applied to “diagnostic delay” or “diagnostic interval”, taking the
time between first symptom or a positive screening test and either the histological diagnosis [9,23–25],
or the commencement of treatment [6,7,26]. For symptomatic breast cancer, diagnostic intervals can
be impacted by “patient-related intervals” includes the time from first noticing a symptom to first
medical appointment, and/or “system-related intervals”, i.e., the time from first medical appointment
to histological diagnosis.
An earlier systematic review published in 1999 found studies examining patient delay by and
large, relied on small sample sizes, the non-standardised collection of secondary data, for example
medical records, and did not include the underlying reasons why a patient may delay seeking
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medical attention [27]. While some recent studies have addressed some of the previously identified
weaknesses, such as addressing the psychosocial factors that may predict risk of delay [8,28], others
have focused on subgroups (such as young or low income women, early breast cancer only) [23,24,29],
or have not included reasons for delay [26,30,31]. It has been suggested that the patient-related
interval may be influenced by a number of factors including: “demographic factors” (such as age,
education); “psychological factors” (such as fear and anxiety); “social factors” (such as work and
family commitments); “behavioural factors” (such as symptom recognition, awareness and watchful
waiting); and “system factors” (such as access, difficulties in making appointments, distance to medical
services, coordination of diagnostic tests, and inadequate communication between and within medical
services) [32]. Exclusion of the underlying reasons for longer patient intervals or other potentially
important covariates, limits our ability to intervene to reduce the patient- and system-related intervals.
Australia is a geographically large country where diagnostic and treatment services are
concentrated in major cities. To our knowledge, there have been no large-scale studies conducted in an
Australian population examining the extent to which patient and system factors impact diagnostic
intervals. To address this issue we undertook a large population-based longitudinal study of women
newly diagnosed with breast cancer in Queensland, to identify predictors of overall diagnostic delay,
and patient- and system-related intervals, and to examine reasons for longer intervals.
2. Materials and Methods
The Breast Cancer Outcomes study (BCOS) is a longitudinal study among women aged 20 to
79 years newly diagnosed with invasive breast cancer in Queensland, Australia [33].
2.1. Ethics
Ethical approval for this study was obtained from the Human Research Ethics Committee of
Griffith University, Australia (PSY/C4/09/HREC). Approval to access confidential health information
was obtained from the Research Ethics and Governance Unit, Queensland Health.
2.2. Study Population
All female residents of Queensland, Australia with a histologically confirmed first primary
invasive breast cancer diagnosed between 1 January 2011 and 30 June 2013, aged 20 to 79 years,
and notified to the Queensland Cancer Registry were eligible for the study. Cancer notifications have
been a legal requirement in Queensland since 1982. Eligible women were required to speak and
understand English and have no cognitive impairment that would preclude them participating in a
telephone interview.
2.3. Recruitment
Letters explaining the study and seeking permission to contact women were sent to all treating
doctors. A reminder letter was sent to non-responding doctors approximately two weeks later followed
by a telephone call after a further two weeks. Women for whom doctor’s permission was obtained
were invited by letter to participate. Non-responders were re-mailed two weeks after the initial mailout
and followed by a telephone call after a further two weeks.
We identified 5426 women of whom 66 were deceased. Of the remaining 5360 women, doctor
consent was not obtained for 688 (12.8%). The most common reasons doctors cited for refusing consent
were their patient was too ill or they did not believe their patient would manage or be interested in
participating in the study. Of those with doctor consent (n = 4762), consent was received from a total
of 3480 women (74.4%) and 3326 eligible women completed the interview (71.2%). There were no
significant differences between participants and non-participants in relation to age (p = 0.33), however
women living in major cities were less likely to participate (p = 0.04), and non-participants were more
likely to be diagnosed with advanced disease (p = 0.03).
Int. J. Environ. Res. Public Health 2016, 13, 1156 4 of 20
As the purpose of this study was to examine diagnostic intervals, including the patient and
system components, we excluded 124 women whose breast cancer was initially detected by their
doctor (through a clinical breast examination or incidentally). Thus, the final cohort consisted of
3202 participants.
2.4. Data Collection
Full details of data collection have been described previously [33]. A validated, semi-structured
telephone interview administered by trained health interviewers was used to construct each woman’s
pathway to their breast cancer diagnosis. Two groups were defined; symptom-detected and
screen-detected. The symptom-detected group included women who first noticed a sign or symptom
of breast cancer or where a layperson initially detected a sign or symptom suspicious of breast cancer.
The screen-detected group represented women where the suspicion of breast cancer was made on
routine mammography or ultrasound.
To ascertain how the breast cancer was detected, participants were asked “How was your breast
cancer first detected, and by that I mean who was the very first person who thought or noticed
something might be wrong?” If a participant indicated her breast cancer was detected during a
screening examination, the interviewer probed further to ensure there was no suspicion of breast
cancer prior to the screening examination.
Women were asked for the date they first noticed the symptoms or when the screening test was
conducted, the date they first consulted a doctor, the outcome of the appointment (given all clear,
wait and monitor, referred, ordered tests), type and date of subsequent procedures and where longer
intervals occurred, the reasons for the delay up to the date of confirmed diagnosis. To maximise
accuracy, women were provided with the relevant questions prior to their interview and asked to
document their responses after consulting their diaries/calendars and/or their doctors. Interviewers
used various probes to help with recall as have been used in other studies [26,34,35]. In a random
sample of 500 women, the accuracy of self-reported dates of screening and medical appointments
was found to be high when checked against medical records. For example, in screen-detected cases
(n = 290), 85% reported a date within two days of the true date of screening, and for symptom-detected
cases (n = 210), 70% reported a date of initial medical appointment within a few days of the correct
date. While accuracy was slightly lower for older women, there were no significant differences in
accuracy according to remoteness or area-level disadvantage.
We collected sociodemographic information pertaining to age, education, marital status,
employment, health insurance status, gross household income and residential location. Clinical coders
extracted relevant data items from histopathology reports including date of diagnosis, tumour site and
size, morphology, histological grade, degree of lymph node involvement, oestrogen, progesterone and
Herceptin status, and stage was assigned according to the American Joint Committee Cancer Staging
Manual [36]. Tumour size was determined as the diameter of the invasive component of the tumour,
or in the case of multicentric tumours, the largest tumour diameter was used.
Remoteness of residence at diagnosis was categorized using the ARIA+ classification, which is a
measure of accessibility and remoteness based on geographical location [37]. Area-level socioeconomic
disadvantage was measured using the Index of Relative Socioeconomic Disadvantage (IRSD) 2011
version calculated by the Australian Bureau of Statistics (ABS) (Canberra, Australia) [38].
Mean time from diagnosis to interview was 6.8 months (range = 3.4. to 18.5 months) with over
80% of the study cohort being interviewed within 10 months of diagnosis. On average the baseline
interview took 60 min (range 15 to 90 min).
2.5. Study Outcomes
Diagnostic interval (DI) was defined as the number of days between first detecting a sign
or symptom (for the symptom-detected group), or date of mammogram and/or ultrasound
(for screen-detected group) to the date of a biopsy proven breast cancer.
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For the symptom-detected group, DI was further subdivided into patient-related interval (PI)
defined as the number of days between first noticing the symptom to date of first medical appointment
and system-related interval (SI), defined as the time from first medical appointment to diagnosis.
While there is some overlap between the patient and system components, these definitions focus on
who was initiating the action. Participants were additionally asked the reasons for the delay (multiple
responses allowed). As suggested by others [32,39], reasons for either PI or SI were then collapsed
into four main themes: competing priorities of the patient (including work or home/family priorities,
other medical problems); awareness and symptom recognition (including symptoms not important, had
been monitoring the symptoms, decided to wait for regular appointment); fear and anxiety (including
was worried what might be found, did not like going to doctors); and system related factors (including
difficulty in obtaining an appointment, distance or difficulty in getting to the doctor, costs).
For screen-detected breast cancers, while other studies have included a definition for PI as the
time from mammogram (and/or ultrasound) appointment to first medical procedure [26], this does
not take into account the time from mammogram to notification of results which can be impacted by
both patient and system factors (screening facility tried to contact patient; notified of results but took
some time to contact doctor for follow-up; time taken to view and report on mammogram, referrals
from screening facility to patient’s GP or specialist). Thus we defined DI for screen-detected cases as
the time from mammogram to confirmatory biopsy. We further examined time from mammogram to
receipt of results separately.
2.6. Predictors of Delay
We examined the impact of various patient, clinical and health system factors for DI for both
groups. These factors included age at diagnosis; Indigenous status; education; employment; gross
household income; private health insurance; family history of breast cancer; comorbidities; history
of benign breast disease; history of breast self-examination and mammography; whether participant
had discussed with a partner/family/friend their concerns about a symptom of breast cancer
(for symptom-detected); degree of remoteness; area-level disadvantage; tumour size and grade;
and nodal status. We additionally examined these same factors in relation to PI and SI for women with
symptom-detected breast cancers.
2.7. Statistical Analysis
The statistical significance of bivariate comparisons between DI, PI and SI and various
sociodemographic and clinical factors for symptom- and screen-detected breast cancers was estimated
using the chi-square test. As the distribution of days was highly skewed we have reported median
values along with 25th and 75th percentiles for DI, PI and SI.
We used separate logistic regression models to examine factors independently associated with
DI according to detection method. For symptom-detected breast cancers the outcome variable for DI
was >60 days vs. ≤60 days which was selected based on previously published work [28], with the
outcome variable for both PI and SI being >30 days vs. ≤30 days. For screen-detected breast cancer,
DI delay was defined as >30 days vs. ≤30 days. The shorter time interval for screen-detected breast
cancers was selected based on the literature recommending time from abnormal mammogram to
diagnostic procedures should be within approximately 30 days [22]. The outcome variable for time
from mammogram to receipt of results was defined as >14 days vs. ≤14 days, based on BreastScreen
Australia’s accreditation standards [20].
For each model, we began with a full logistic model including all variables relating to either
symptom- or screen-detected breast cancer along with the clinical characteristics of the breast cancer.
Variables not associated with the outcome were then excluded manually on a one-by-one basis using a
significance level of >0.20, the model re-run and the likelihood ratio (LR) test was examined at each
stage of the variable exclusion process. Excluded variables were then re-introduced into subsequent
models and the LR test re-examined to ensure variables associated with the outcome were not excluded.
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As individuals living in remote and very remote areas are also more likely to live in a socioeconomically
disadvantaged area [40], we added an interaction term to examine if associations between DI and
area-level disadvantage was different across various levels of remoteness. All analyses were conducted
using Stata14.0. (Stata Corp, College Station, TX, USA).
3. Results
3.1. Description of the Cohort
The cohort included 1560 women with symptom-detected and 1642 women with screen-detected
breast cancer. Mean age was 57 years (54 years for symptom- and 60 years for screen-detected).
Just under half were diagnosed with stage I breast cancer (48.6%), 38.8% with stage II, 11.1% with stage
III/IV and the remaining 1.6% of women were unable to be staged. Just over half (55.1%) lived in major
cities, 24.0% in inner regional areas and the remainder (20.9%) lived in outer regional or remote/very
remote areas. Nearly two-thirds reported they had full private health insurance (63.5%), 10.4% had
some health insurance and the remainder (26.1%) had no health insurance (data not shown).
3.2. Symptom-Detected Breast Cancer
Median time to diagnosis from recognition of own symptoms was 25 days (25th percentile = 11 days
and 75th percentile = 63 days). Just over a quarter (26.5%) experienced a delay of >60 days and 18%
experienced delays of >90 days. Table 1 shows the proportion of women with symptom-detected
breast cancer where the DI was >60 days according to sociodemographic, screening history and clinical
characteristics of the breast cancer. The proportion of women with DI > 60 days was higher for
Indigenous women (p = 0.006), women in outer regional and remote/very remote areas (p = 0.003),
those whose tumour was classified as low grade (p < 0.001), women who did not indicate a breast lump
was at least one of her symptoms (p < 0.001), and for women who had not discussed their symptom
with someone close to them prior to their initial medical appointment (p = 0.05).
3.2.1. Factors Associated with Diagnostic Delay
Table 1 presents the results of the multivariable logistic regression model for symptom-detected
breast cancers including all factors found to be significantly associated with the diagnostic interval.
The odds of a DI of >60 days were higher women who were Indigenous (OR = 3.12, 95% CI = 1.40, 6.98)
compared to non-Indigenous; lived in an outer regional (OR = 1.50, 95% CI = 1.09, 2.06) or remote/very
remote locations (OR = 2.46, 95% CI = 1.39, 4.38) compared to those in major cities. Other independent
predictors of a longer DI included the absence of a breast lump as a presenting symptom (OR = 1.84,
95% CI = 1.43, 2.36). Tumour size was not associated with DI, however women whose tumours were
high compared to low grade had a lower odds of a longer DI (OR = 0.49, 95% CI = 0.33–0.73).
3.2.2. Patient-Related Interval
Of the 1560 women with symptom-detected breast cancer, 54.7% presented to their medical
practitioner within 14 days of symptom discovery, 71.6% within 30 days and 85.3% within 60 days.
In the multivariable logistic regression model (Table 2), factors independently associated with a longer
PI included the absence of a breast lump as a presenting symptom (OR = 1.88, 95% CI = 1.47, 2.39)
and not discussing symptom discovery with someone other than a doctor (OR = 1.48, 95% CI = 1.16,
1.88). Further the odds of a longer PI was higher for women who had no or infrequent mammograms
compared to those reporting regular mammography (OR = 1.35, 95% CI = 1.06–1.73), with the direction
and strength of this association remaining when we restricted the analysis to women aged 50 to
69 years. Age group, location of residence, area-level disadvantage, education, employment and
private health insurance were not independently associated with PI. These results were similar when
we defined PI as more than 60 or 90 days.
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Table 1. Relationship between diagnostic interval and sociodemographic and clinical variables
amongst 1560 women in Queensland, Australia with symptom-detected breast cancer: results of
logistic regression model.
Variable % Interval
>60 Days
Crude
p-Value
Diagnostic Interval≤60 Days vs. >60 Days
Adjusted
Odds Ratio 1 95% CI p-Value
Age group 0.53 0.41
<50 years (n = 624) 27.4 1.12
0.86, 1.4650–79 years (n = 936) 26.0 ref
Indigenous status 0.006 0.005
Non-indigenous (n = 1534) 26.1 ref
1.40, 6.98Indigenous (n = 26) 50.0 3.12
Residential location 0.003 0.003
Major city (n = 854) 23.4 ref
Inner regional (n = 388) 28.4 1.28 0.96, 1.69
Outer regional (n = 263) 30.8 1.50 1.09, 2.06
Remote/very remote (n = 55) 41.8 2.46 1.39, 4.38
Area-level disadvantage 0.10
Least disadvantaged (n = 658) 23.9
Middle socioeconomic status (n = 336) 27.4 - - -
Most disadvantaged (n = 566) 29.2
Marital status 0.70 -
Married/living as married (n = 1142) 26.8 - - -
Not married/not living as married (n = 418) 25.8
Education 0.77
High school or less (n = 597) 26.3
Certificate/vocational (n = 346) 28.0 - - -
Diploma/Batchelors or higher (n = 617) 25.9
Employment status 0.07 0.10
Full-time (n = 559) 32.0 1.45 1.03, 2.06
Part-time/casual (n = 458) 26.0 1.32 0.92, 1.89
Home duties/not working (n = 178) 28.1 1.44 1.01, 2.04
Retired (n = 365) 22.2 ref
Private health insurance 0.30
Full (n = 935) 25.8
Some (n = 158) 31.7 - - -
None (n = 467) 26.3
Frequency of mammogram 0.25
At least once every 2 years (n = 795) 25.3 - - -
Irregular/never (n = 765) 27.8
Presence of breast lump <0.001 <0.001
Yes (n = 1121) 22.7 ref
No (n = 439) 36.4 1.84 1.43, 2.36
Discussed symptoms with someone 2 0.05 0.06
Yes (n = 1056) 25.0 ref
No (n = 504) 29.8 1.27 0.99, 1.63
Tumour size 0.03 0.68
<1.0 cm (n = 186) 31.2 ref
≥1.0 cm to <2 cm (n = 516) 24.4 0.82 0.56, 1.21
≥2.0 cm (n = 804) 25.9 0.95 0.65, 1.38
Unknown (n = 54) 40.7 1.00 0.47, 2.11
Histological grade <0.001 <0.001
Low (n = 175) 34.3 ref
Intermediate (n = 676) 29.1 0.77 0.53, 1.11
High (n = 676) 20.3 0.49 0.33, 0.73
Unknown (n = 33) 60.6 2.58 1.06, 6.27
1 Logistic model adjusted for age group, Indigenous status, residential location, pre-diagnosis employment,
whether presenting symptom included breast lump; 2 participant discussed symptoms with someone other
than a health professional; dashes indicate variable not included in final model.
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Table 2. Multivariable logistic regression model showing factors associated with patient-related interval
for 1560 women with symptom-detected breast cancer.
Variable
% Interval
>30 Days
Crude
p-Value
Patient-Related Interval≤30 Days vs. >30 Days
Adjusted
Odds Ratio 1 95% CI p-Value
Age group 0.37 0.6
20–49 years (n = 624) 29.6 1.07
0.82, 1.4150–79 years (n = 936) 27.6 ref
Area-level disadvantage 0.14 0.12
Least disadvantaged (n = 658) 27.2 ref
Middle SES (n = 336) 32.7 1.34 1.00, 1.79
Most disadvantaged (n = 566) 27.2 1.03 0.79, 1.34
Employment status 0.08 0.15
Full-time (n = 559) 32.0 1.43 1.02, 2.00
Part-time/casual (n = 458) 26.9 1.13 0.79, 1.61
Home duties/not working (n = 178) 28.6 1.20 0.78, 1.85
Retired (n = 365) 24.7 ref
Frequency of mammogram 0.005 0.02
At least once every 2 years (n = 795) 25.3 ref
Irregular/never (n = 765) 31.6 1.35 1.06, 1.73
Presence of breast lump <0.001 <0.001
Yes (n = 1121) 24.4 ref
No (n = 439) 38.5 1.88 1.47, 2.39
Discussed symptoms with someone 2 0.001 0.002
Yes (n = 1056) 25.8 ref
No (n = 504) 33.9 1.48 1.16, 1.88
Histological grade 0.002 0.007
Low (n = 175) 35.4 ref
Intermediate (n = 676) 29.1 0.72 0.50, 1.04
High (n = 676) 24.9 0.61 0.42, 0.87
Unknown (n = 33) 48.5 1.56 0.72, 3.37
1 Logistic model adjusted for all other variables shown in the table; 2 Participant discussed breast cancer
symptoms with someone other than a health professional.
For women who indicated a delay in seeing a medical practitioner or in making an appointment
at a screening facility (n = 130), the most common reasons for delay were: lack of awareness of possible
symptoms of breast cancer (47.9%); work or family priorities (39.2%); system difficulties (i.e., obtaining
appointments or distance to doctor) (26.2%); and fear or anxiety for what might be found (4.9%).
A significantly higher proportion of women in regional and remote/very remote locations cited delays
in obtaining medical appointments or difficulties in travel time to their doctor (33.9% and 19.2%,
respectively, p < 0.001). Additionally, women with lower levels of education were more likely to
indicate they did not think the symptom was important or it would go away compared to those with
post-high school qualifications (53.7% and 44.3%, respectively, p = 0.01) (data not shown).
3.2.3. System Delay
Overall, 38.1% of participants were diagnosed within seven days of their initial medical
consultation, 62.2% within 14 days and 84.3% within 30 days (the vast majority of women saw a
GP for their initial consultation). In the multivariable logistic regression model, where SI was defined
as delays of >30 days (Table 3), women living in outer regional areas compared to major cities, and
women in areas of disadvantage had a higher odds of a longer SI (OR = 1.61, 95% CI = 1.10, 2.35
and OR = 1.42, 95% CI = 1.02, 2.12, respectively). Tests for an interaction between remoteness and
area-level disadvantage and SI were not significant (p = 0.45). Compared to women who were retired,
women employed full-time were nearly three times more likely to experience a longer SI (OR = 2.87,
95% CI = 1.72, 4.81) while those with larger and high grade tumours had a lower odds of SI, (Table 3).
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Table 3. Multivariable logistic regression model showing factors associated with system-related interval
for 1560 women with symptom-detected breast cancer.
Variable
% Interval
>30 Days
Crude
p-Value
System-Related Interval≤30 Days vs. >30 Days
Adjusted
Odds Ratio 1 95% CI p-Value
Age group 0.16 0.15
20–49 years (n = 624) 17.3 1.26
0.91, 1.7450–79 years (n = 936) 14.6 ref
Residential location 0.05 0.01
Major city (n = 854) 13.8 ref
Inner regional (n = 388) 16.2 1.20 0.84, 1.70
Outer regional (n = 263) 19.8 1.61 1.10, 2.35
Remote/very remote (n = 55) 21.8 1.85 1.00, 3.66
Area-level disadvantage 0.003 0.008
Least disadvantaged (n = 658) 12.9 ref
Middle SES (n = 336) 14.3 1.21 0.81, 1.80
Most disadvantaged (n = 566) 19.8 1.42 1.02, 2.12
Employment status <0.001 0.002
Full-time (n = 559) 25.8 2.87 1.72, 4.81
Part-time/casual (n = 458) 15.4 1.56 1.00, 2.45
Home duties/not working (n = 178) 15.7 1.61 1.01, 2.55
Retired (n = 365) 11.2 ref
Presence of breast lump <0.001 <0.001
Yes (n = 1121) 12.6 ref
No (n = 439) 23.7 2 1.49, 2.70
Tumour size 0.006 0.07
<1.0 cm (n = 186) 23.1 ref
≥1.0 cm to <2.0 cm (n = 516) 14.3 0.40, 0.97
≥2.0 cm (n = 804) 14.3 0.44, 1.04
Unknown (n = 54) 24.1 0.13, 0.92
Histological grade <0.001 <0.001
Low (n = 175) 18.9 ref
Intermediate (n = 676) 19.4 1.06 0.68, 1.66
High (n = 676) 9.4 0.48 0.30, 0.79
Unknown (n = 33) 51.5 7.11 2.61, 19.36
1 Logistic model adjusted for all other variables shown in the table.
Participants reported various combinations of diagnostic procedures were conducted with the
most common pathway following initial medical consultation being a clinical breast examination,
mammogram, ultrasound and biopsy. Just under a quarter cited a delay (defined as 14 days or more)
with their mammogram (23.5%), 25.9% a delay with an ultrasound and 31.7% experienced delay
with their biopsy. The most common reason for delays was difficulties in obtaining or coordinating
appointments for the procedures. For example, for participants who had a delay in their biopsy, 81.3%
indicated this was due to difficulties in obtaining an appointment and this was significantly more
common for women in regional and remote/very remote areas than for those in major cities (85.6% vs.
70.0%, p = 0.03).
3.3. Screen-Detected Breast Cancer
3.3.1. Interval from Mammogram to Receipt of Results
For women whose breast cancer was screen-detected (n = 1642), median time to receive abnormal
mammogram results was seven days with most women notified within 14 days (80.5%). Table 4
presents the results of a fully adjusted logistic regression model examining factors associated with an
interval of more than 14 days in receipt of mammogram results. The odds of a longer interval were
higher for women in outer regional and remote areas (OR = 4.17, 95% CI = 2.95, 5.91 and OR = 3.62,
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95% CI = 2.00, 6.55, respectively) compared to those in major cities and for women who had their
mammogram in a public facility (BreastScreen or public hospital) (OR = 9.51, 95% CI = 5.21, 17.36)
compared to private facilities. Further, women with tumours ≥1 cm had a lower odds of delay in
receipt of results than women with tumours of less than 1 cm (p = 0.01).
Table 4. Factors associated with delays in receiving mammogram results in 1642 women with
screen-detected breast cancer: results of logistic regression model.
Variable
% >14
Days
Crude
p-Value
Received Mammogram Results≤14 Days vs. >14 Days
Adjusted Odds
Ratio 1 95% CI p-Value
Age 0.65 0.2
<50 years (n = 239) 18.4 1.29
0.87,1.9050–79 years (n = 1403) 19.7 ref
Residential location <0.001 <0.001
Major city (n = 910) 11.0 ref
Inner regional (n = 380) 20.5 1.71 1.20, 2.44
Outer regional (n = 291) 40.6 4.17 2.95, 5.91
Remote/very remote (n = 61) 39.3 3.62 2.00, 6.54
Area-level disadvantage <0.001 0.07
Least disadvantaged (n = 707) 12.3 ref
Middle socioeconomic status (n = 329) 19.2 1.38 0.94, 2.02
Most disadvantaged (n = 606) 28.1 1.45 1.04, 2.01
Type of screening facility <0.001 <0.001
BreastScreen (n = 1233) 25.0 9.51
5.21, 17.36Private (n = 409) 2.9 ref
Tumour size 0.06 0.01
<1.0 cm (n = 625) 21.1 ref
≥1.0 cm to <2 cm (n = 694) 18.6 0.66 0.49, 0.88
≥2.0 cm (n = 316) 18.0 0.63 0.44, 0.92
Missing (n = 7) 28.6 3.15 0.41, 24.01
1 Logistic model adjusted for all other variables shown in the table.
3.3.2. Diagnostic Delay
The median time between abnormal mammogram and diagnosis was 14 days. While only a
minority of women (16.4%) had a diagnostic interval more than 30 days, some groups were more likely
to experience intervals beyond 30 days (Table 5). At a bivariate level (percentages shown in Table 5),
women who were Indigenous (p < 0.001); lived in outer regional and remote locations (p < 0.001) or
disadvantaged areas (p < 0.001); those without private health insurance (p = 0.007); and where the
screening facility was public (p < 0.001) were all more likely to experience a DI greater than 30 days.
No significant bivariate associations were found for any other sociodemographic variables.
After adjustment, the odds of experiencing a longer DI for women with screen-detected
breast cancer (Table 5) were higher for Indigenous women (OR = 2.36, 95% CI = 1.03, 5.80) than
non-Indigenous women, and women from outer regional (OR = 3.32, 95% CI = 2.31, 4.75) and remote
locations (OR = 2.35, 95% CI = 1.24, 4.44) compared to those in major cities. Additionally, compared to
women from more socioeconomically advantaged areas, women from areas of middle socioeconomic
status and those from areas of disadvantage had a higher odds of a longer DI (OR = 1.58, 95% CI = 1.03,
2.56 and OR = 1.69, 95% CI = 1.17, 2.43, respectively). Further, the odds of a longer DI was significantly
higher for women whose mammogram was conducted in a public screening facility compared to those
attending a private facility (OR = 2.10, 95% CI = 1.40, 3.17).
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Table 5. Relationship between diagnostic delay and sociodemographic and clinical variables amongst
1642 women in Queensland, Australia with screen-detected breast cancer.
Variable
% Interval
>30 Days
Crude
p-Value
Diagnostic Interval≤30 Days vs. >30 Days
Adjusted
Odds Ratio 1 95% CI p-Value
Age 0.68 0.43
20–49 years (n = 239) 15.5 0.84 0.54, 1.30
50–79 years (n = 1403) 16.5 ref
Indigenous status 0.02 0.04
Non-indigenous (n = 1618) 16.1 ref
Indigenous (n = 24) 33.3 2.36 1.03, 5.80
Residential location <0.001 <0.001
Major city (n = 910) 10.1 ref
Inner regional (n = 380) 16.6 1.41 0.97, 2.04
Outer regional (n = 291) 33.0 3.32 2.31, 4.75
Remote/very remote (n = 61) 29.5 2.35 1.24, 4.44
Area-level disadvantage <0.001 0.002
Least disadvantaged (n = 707) 9.5 ref
Middle socioeconomic status (n = 329) 18.8 1.58 1.03, 2.56
Most disadvantaged (n = 606) 23.1 1.69 1.17, 2.43
Marital status 0.81
Married/living as married (n = 1217) 16.5
Not married/not living as married (n = 425) 16.0 - - -
Education 0.28
High school or less (n = 648) 17.4
Certificate/vocational (n = 424) 17.5 - - -
Diploma/Bachelor’s or higher (n = 570) 14.4
Employment status 0.04 0.03
Full-time (n = 438) 23.1 1.70 1.13, 2.44
Part-time/casual (n = 435) 17.8 1.64 1.02, 2.63
Home duties/not working (n = 160) 16.6 1.39 0.96, 2.02
Retired (n = 609) 13.5 ref
Private health insurance 0.007 0.32
Full (n = 1097) 14.6 ref
Some (n = 174) 16.7 1.00 0.63, 1.60
None (n = 371) 21.6 1.28 0.92, 1.78
Frequency of mammography 0.07
At least once every 2 years (n = 1412) 15.7 - - -
Irregular/never (n = 230) 20.4
Type of screening facility <0.001 <0.001
BreastScreen (n = 1233) 19.2 2.10 1.40, 3.17
Private (n = 409) 7.8 ref
Tumour size 0.009
<1.0 cm (n = 625) 19.5
≥1.0 cm to <2 cm (n = 694) 14.6 - -
≥2.0 cm (n = 316) 13.6
Missing (n = 7) 42.9
Histological grade 0.03
Low (n = 419) 19.8
Intermediate (n = 848) 15.6 - -
High (n = 368) 13.9
Unknown (n = 7) 42.9 -
Lymph nodes involved <0.001 <0.001
No (n = 1246) 15.6 ref
Yes (n = 369) 16.3 0.98 0.71, 1.37
Unknown (n = 27) 51.8 6.68 2.90, 15.39
1 Logistic regression model adjusted for age group, Indigenous status, residential location, private health
insurance, pre-diagnosis employment, type of screening facility, tumour size and grade, and nodal status;
dashes indicate variable not included in final model.
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3.3.3. Reasons for Delay
Most common reasons women cited for a delay from their mammogram to diagnosis were again
difficulties in obtaining or coordinating appointments for ultrasounds and biopsies (67.4%), along with
work or family commitments (38.4%).
4. Discussion
This study examined diagnostic intervals in a large cohort of women with either symptom- or
screen-detected breast cancer. For symptom-detected breast cancer median interval between symptom
and diagnosis was 25 days, while for screen-detected breast cancer, the median interval from screen
to diagnosis was 14 days. These intervals are not excessive from the viewpoint of breast cancer
biology [5], however, from the patient viewpoint, waiting for confirmation of a diagnosis is an anxious
and stressful time [12,41]. In this study, while we found the majority of symptom-detected breast
cancer was diagnosed within 90 days, it remained that one in five women experienced a delay of
greater than 90 days, the time at which survival can be impacted [11,42]. For example, Richards et al. [11]
found women with delays of greater than 12 week had 12% lower five-year survival compared to those
with shorter (<12 weeks) intervals. For both symptom- and screen-detected breast cancer, we found
women living in more geographically isolated areas, areas of disadvantage and Indigenous women
were more likely to experience longer diagnostic intervals compared with women from major cities,
more socioeconomically advantaged areas and non-Indigenous women. We identified a number of
factors associated with longer patient and system intervals.
4.1. Symptom-Detected Breast Cancer
In this study while the majority of women were diagnosed within 60 days, just over a quarter
(26.5%) experienced a diagnostic interval of more than 60 days and 18% experienced intervals of more
than 90 days. Two systematic reviews including one meta-analysis, identified delays of 90 days or
more were associated with later stage breast cancer and poorer survival [11,42]. While in our study
we have not conducted a survival analysis, we did find women who experienced a DI of more than
60 days were significantly more likely to be diagnosed with stage III or IV disease with this association
remaining after adjustment for tumour grade.
Patient-related interval: The time from symptom discovery to diagnosis includes periods where
patient and/or system (medical) factors can impact overall time to diagnosis. Amongst our cohort, the
median time from breast cancer symptom to initial medical consultation was 11 days. This is similar to
that observed in more recent breast cancer cohorts in the United Kingdom (median of 13 days) [43],
New Zealand (median of 14 days) [44], and Germany (median of 16 days) [8]. Our results also add
to the growing trend for shorter patient delays to that observed in earlier studies [45,46]. However,
it remained in our study that one in seven women waited more than 60 days and one in ten women
waited more than 90 days to consult their doctor.
A longer patient interval was not associated with age, geographical location or with most other
sociodemographic factors. While Indigenous women were more likely to experience longer overall
diagnostic intervals (mainly driven by system delay), they were no more or less likely than their
non-Indigenous counterparts to delay initial presentation to their doctor. These results are similar to
that observed in New Zealand amongst Maori and Pacific Islander women [44]. However, delays in
patient presentation have been reported for a number of ethnicities including Asian, Middle Eastern
and African Americans [9,25,47–49].
The strongest risk factor for a longer patient interval in this study was the lack of a breast lump as a
symptom, with this nearly doubling the risk of delayed presentation. While the majority of women with
symptom-detected breast cancer noticed a breast lump (72%), those who did not commonly indicated
they noticed a change in breast shape, sensory changes, red or inverted nipple. Similar findings have
been observed in other cohorts where the presence of a symptom other than a breast lump increases
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the risk of later presentation [7,8]. It is suggested that women with “non-lump symptoms” are less
likely to attribute that symptom to breast cancer and more likely to delay presentation [7,39]. Further,
our finding that women who did not discuss their breast cancer symptom(s) with someone other than
their doctor were more likely to delay presentation, is also in keeping with other studies [7,27,46].
Burgess et al. found the likelihood a woman would discuss her concerns was associated with whether
they lived with a partner [7]. Similarly, in our study, we found significantly more women who were
married or living as married discussed their concerns compared to those without partners.
We found the most common reason women identified for delayed presentation was a lack of
awareness of breast cancer symptoms (48%). This is similar to that observed in other studies where
over 40% of women who delayed consulting a medical practitioner thought the symptom would go
away or was not serious [43]. Current recommendations from health authorities advise that women
should be aware of changes such as presence of a breast lump; change in breast size or shape; changes
to nipple (including discharge, redness); change in skin or unusual pain [50]. The results in our study
indicate a need to continue educating women on the importance of timely medical consultation and an
awareness of all potential breast cancer symptoms.
System-related interval: While geographic location and area-level disadvantage were not associated
with a longer patient-related interval, these factors were strongly associated with intervals of more than
30 days from first medical consultation to diagnosis. Compared to women in major city areas, those
living in outer regional and in areas of disadvantage were some 40%–60% more likely to experience a
longer SI. This is consistent with other studies, for example, a small study conducted in Iowa, USA
found rural women were less likely to receive adequate follow-up diagnostic services, including
longer time intervals [51], and Crispo and colleagues who defined system (medical) delay as the time
from first physical examination to hospital admittance, found women who attended facilities outside
specialist breast health services (mainly located within urban areas) were more likely to experience
delays in diagnosis [26].
Of the other sociodemographic factors, we found no independent association with age, education
or marital status, but did find that women in full-time employment were more likely to experience
a longer system-related interval. While we were unable to find other studies reporting a similar
association between employment status and system delay, some studies have reported work and
family commitments are factors associated with patient delay [8,44]. It is possible work commitments
may hinder making (and keeping) appointments for diagnostic procedures.
Difficulties in access to procedures such as mammography and diagnostic biopsy has been
identified as barriers to timely diagnosis in previous studies [52]. In our cohort, women in regional
and remote/very remote areas commonly cited difficulties in obtaining appointments in primary care,
as well as coordinating appointments for diagnostic procedures. In particular, women in outer regional
and remote/very remote areas indicated delays occurred from the initial diagnostic procedures (most
commonly clinical breast examination and then mammogram) to diagnostic biopsy (fine needle
aspiration or core biopsy). One of the likely reasons for this differential is the limited availability of
experienced personnel able to conduct these procedures outside major diagnostic facilities [53]. In a
study among rural patients in Western Australia, researchers identified difficulties in timely access
to ultrasound-guided breast biopsy as this procedure was not readily available locally [54]. Further,
a qualitative study amongst GPs in rural Australia, found one of the emerging themes related to
difficulties in coordinating diagnostic procedures for patients who require extensive travel, and GPs
additionally felt current guidelines for managing the diagnostic pathway do not take into account the
rural practice setting [55].
Improving GP access to regional and rural diagnostic services and timely access to relevant
diagnostic procedures would likely result in a reduction in the disparity in system-related intervals
between rural and urban breast cancer patients over time. A number of countries have introduced
recommended pathways for referral and diagnosis [56–59]. Evaluation of the effectivness of such
pathways has been conducted in Denmark with findings indicating a reduction in the interval between
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initial GP consultation and diagnosis, with the greatest improvement observed for breast cancer [60].
However, as the evaluation did not examine rural and urban patients separately, it is difficult to know
whether such a model would be effective in the Australian setting.
In Australia, while GPs have access to guidelines to assist them in investigating a new breast
symptom, these do not include a recommended time frame for investigations to be completed [18].
We are aware of only one other small case series conducted in regional Australia that examined
the various components of the diagnostic pathway and found the median interval from symptom
awareness to GP consultation was 55 days and from GP consultation to definitive diagnosis was
20 days [61].
Diagnostic interval: We did find some women were less likely to experience longer diagnostic
intervals. The factors associated with less likelihood of a longer DI mostly related to the clinical
characteristics of the breast cancer. For example, women with high grade tumours were nearly 50%
less likely to experience a longer DI, with this suggesting a rapidly growing breast lump most likely
prompts patients to consult their doctor quickly. Similar results have been observed in other studies.
For example, Redondo and colleagues found diagnostic delays of less than 30 days were significantly
associated with increased tumour size and poorly differentiated tumours [62].
4.2. Screen-Detected Breast Cancer
Approximately 80% of participants in our study received their mammogram results within
14 days. BreastScreen Australia standards state that 90% of all women screened should receive their
results within 14 days [20]. Receipt of results varied significantly by residential location with only 60%
of women in outer regional and remote locations receiving results within 14 days compared to 90% of
women in major city areas (independent of tumour size). We additionally found shorter time intervals
in notification of results for women whose mammogram was conducted at a private facility, with the
majority of those women being notified within two days. While we are not aware of any other studies
conducted in Australia reporting on time intervals from mammogram to notification of results within
private screening facilities, our results are in agreement with studies using United States of America
(USA) Health Maintenance Organization (HMO) populations, where mammograms are interpreted
by radiologists the next working day and patients notified within 24 to 48 hours after issuing of the
report [63].
In our study median time from abnormal mammogram to diagnosis was 14 days with over 80%
of participants diagnosed within 30 days and 90% within six weeks. Our results are similar to that
of several large USA and Canadian studies reporting median times between 12 and 16 days with
approximately 80% of women diagnosed within 30 days [63–66]. BreastScreen Australia recommends
women with a screen-detected abnormality should be assessed within 28 days, with their most recent
evaluation report indicating around 20% of women were not fully assessed within that time frame [67],
similar to our study results.
The strongest factors associated with a diagnostic interval of more than 30 days were rural
location and having the mammogram conducted within the BreastScreen program. While there are few
studies comparing the diagnostic intervals of screen-detected breast cancer amongst urban and rural
women, a study conducted in New Mexico, USA also found longer times to diagnosis for rural women.
That study also reported that the decline in time to diagnosis over time for women located in urban
areas was not observed for women in rural areas [68]. The authors suggested this trend may have
been due to a decreasing use of excisional biopsies and increasing use of “on-site” core biopsies by
radiologists in urban areas, as has been reported elsewhere [69,70]. This may be the case in our study,
as compared to women from urban areas, those living in rural locations were significantly less likely to
have a core biopsy conducted at the same time as their screening mammogram and/or ultrasound.
We found Indigenous women whose cancer was screen-detected were more likely to experience a
diagnostic interval of more than 30 days compared to non-Indigenous women. Other studies have
reported ethnic disparities associated with diagnostic delay [71,72]. In Australia, Indigenous women
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have lower rates of breast screening [13], more extensive disease at diagnosis [73], and less optimal
clinical management [74]. While we are unable to assess the exact reasons for the longer diagnostic
interval for Indigenous women in our study, it is possible that the differences are caused by issues
with accessibility and potentially a lack of culturally sensitive and appropriate health care. Providing
practical assistance and support for Indigenous women and health care professionals who care for
Indigenous women undergoing diagnostic procedures may help reduce this disparity.
Our results highlight differences in diagnostic intervals for those attending public or private
screening facilities. We found the median time from abnormal mammogram to diagnosis more
than doubled for women attending BreastScreen compared with those attending a private facility.
As expected, in our study we found women were more likely to attend private breast screening
facilities in major cities, however the association between a longer diagnostic interval and public
facilities remained after adjusting for residential location. While comparisons with other studies is
difficult, one large USA study observed that facilities with a larger volume of patients (hospital-based
screening facilities) were more likely to have long follow-up times with shorter times observed in HMO
facilities [64]. Identifying methods to collect and assess screening rates and outcomes of screening
among women accessing private breast screening clinics needs to be explored.
4.3. Strengths and Limitations
Strengths of our study are that we were able to include a number of individual socio-economic
measures (such as employment, marital status, education) as well as screening behaviours (such as
frequency of pre-diagnostic mammography and breast self-examination), thus potentially limiting
confounding due to patient factors and behaviours. Further, this large cohort of women was ascertained
through a population-based cancer registry, which may strengthen the potential generalizability
of the findings. We used a structured interview conducted by experienced health interviewers.
The clinical characteristics, including date of diagnosis were obtained through the cancer registry or
from medical records.
Like other studies [34], the retrospective nature of collecting information about dates of symptom
recognition, breast screening, medical consultations and procedures is a limitation of our study. We
attempted to improve the accuracy of recall of events through the use of calendars, interviewer probing
and quantified the level of accuracy by extracting relevant information from medical records for a
random sample of participants. For this group we found reasonable accuracy of recall of events,
particularly in relation to the timing of mammography and medical appointments, and this was similar
across the covariates we used in our analysis. Thus we believe any recall bias is unlikely to impact
on the conclusions of our study. We could not, however, accurately verify the timing of symptom
recognition for women whose breast cancer was symptom-detected, rather we relied on the recall of
each women. Larsen et al. have previously reported moderate agreement between patients and GPs in
relation to the date of symptom recognition and good agreement for the date of initial consultation [75].
While there is likely to be some inaccuracies in the reporting of dates in our study, it is doubtful
there would be any differential bias in the recall of dates of events according to residential location or
other covariates.
5. Conclusions
Our findings indicate significant disparities in the time to diagnosis for both symptom- and
screen-detected breast cancer, with women in regional and remote locations more likely to experience
diagnostic delay. For some women, a lack of awareness of the importance of potential symptoms
of breast cancer resulted in delays in consulting with their medical practitioner. Thus, while in
general there is a need to continue efforts to raise awareness of the symptoms of breast cancer and the
importance of consulting a medical practitioner in a timely manner, approaches targeting those most
at risk of delays in diagnosis should be a priority for public health.
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Rural inequality in cancer outcomes in Australia and elsewhere has been evident for a number
of decades now. Identifying the barriers that drive these inequalities is paramount. This study has
identified some important factors, in particular the difficulty of regional and remote women accessing
primary care. The challenge now is in designing and implementing an efficient and effective model of
care to minimize avoidable delays and to ensure that all women are diagnosed as quickly as possible.
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